![]() |
News Release
Investor Contact:
Maureen Resac
Maureen.Resac@Adtalem.com
312-651-1481
Media Contact:
John Kristoff
John.Kristoff@Adtalem.com
312-651-1437
|
|
•
|
Revenue of $268.2 million increased 5.4% compared to the prior year
|
|
•
|
New and total student enrollment increased 12.2% and 10.8%, respectively
|
|
•
|
Diluted earnings per share was $0.38 compared to diluted earnings per share of $0.26 in the prior year; diluted earnings per share from
continuing operations excluding special items was $0.78 compared to $0.34 in the prior year, a 129% increase
|
|
•
|
Operating income was $36.7 million compared to $25.7 million in the prior year; operating income excluding special items was $54.4 million, a
97.7% increase compared with the prior year
|
|
•
|
Net income attributable to Adtalem was $19.9 million, compared to $14.4 million in the prior year; net income from continuing operations
attributable to Adtalem excluding special items was $41.2 million, a 117.7% increase compared with the prior year
|
|
•
|
COVID-19 pandemic resulted in estimated revenue losses of approximately $14 million, operating income losses of approximately $7 million and loss
of earnings per share of approximately $0.11
|
|
1Q 2021
|
1Q 2020
|
% Change
|
||||||||||
|
Adtalem Global Education Student Enrollments(1)
|
||||||||||||
|
New students
|
7,253
|
6,467
|
+12.2
|
%
|
||||||||
|
Total students
|
41,375
|
37,344
|
+10.8
|
%
|
||||||||
|
Chamberlain University
|
||||||||||||
|
September Session
|
||||||||||||
|
New students
|
6,333
|
5,595
|
+13.2
|
%
|
||||||||
|
Total students
|
35,525
|
31,736
|
+11.9
|
%
|
||||||||
|
July Session(2)
|
||||||||||||
|
New students
|
2,768
|
2,396
|
+15.5
|
%
|
||||||||
|
Total students
|
32,198
|
28,691
|
+12.2
|
%
|
||||||||
|
Medical and Veterinary(3)
|
||||||||||||
|
September Semester
|
||||||||||||
|
New students
|
920
|
872
|
+5.5
|
%
|
||||||||
|
Total students
|
5,850
|
5,608
|
+4.3
|
%
|
||||||||
|
1)
|
Includes the September session enrollments from both Chamberlain University and the Medical and Veterinary institutions
|
|
2)
|
Post-licensure online programs only; Pre-licensure campus-based programs start in September, January and May; Total students includes pre- and
post-licensure enrollment
|
|
3)
|
Includes enrollments in its medical and veterinary preparatory programs
|
|
September 30,
|
June 30,
|
September 30,
|
||||||||||
|
2020
|
2020
|
2019
|
||||||||||
|
Assets:
|
||||||||||||
|
Current assets:
|
||||||||||||
|
Cash and cash equivalents
|
$
|
561,170
|
$
|
500,516
|
$
|
121,079
|
||||||
|
Investments in marketable securities
|
9,434
|
8,968
|
8,763
|
|||||||||
|
Restricted cash
|
947
|
589
|
710
|
|||||||||
|
Accounts receivable, net
|
99,536
|
87,042
|
116,212
|
|||||||||
|
Prepaid expenses and other current assets
|
97,386
|
95,651
|
39,476
|
|||||||||
|
Current assets held for sale
|
—
|
—
|
169,873
|
|||||||||
|
Total current assets
|
768,473
|
692,766
|
456,113
|
|||||||||
|
Noncurrent assets:
|
||||||||||||
|
Property and equipment, net
|
289,944
|
286,102
|
280,823
|
|||||||||
|
Operating lease assets
|
186,824
|
174,935
|
195,238
|
|||||||||
|
Deferred income taxes
|
18,325
|
22,277
|
9,814
|
|||||||||
|
Intangible assets, net
|
285,027
|
287,514
|
295,324
|
|||||||||
|
Goodwill
|
686,480
|
686,214
|
686,992
|
|||||||||
|
Other assets, net
|
94,824
|
78,879
|
91,086
|
|||||||||
|
Noncurrent assets held for sale
|
—
|
—
|
444,934
|
|||||||||
|
Total noncurrent assets
|
1,561,424
|
1,535,921
|
2,004,211
|
|||||||||
|
Total assets
|
$
|
2,329,897
|
$
|
2,228,687
|
$
|
2,460,324
|
||||||
|
Liabilities and shareholders' equity:
|
||||||||||||
|
Current liabilities:
|
||||||||||||
|
Accounts payable
|
$
|
48,148
|
$
|
46,484
|
$
|
44,674
|
||||||
|
Accrued payroll and benefits
|
31,491
|
48,835
|
30,071
|
|||||||||
|
Accrued liabilities
|
107,148
|
104,431
|
61,966
|
|||||||||
|
Deferred revenue
|
168,253
|
91,589
|
168,533
|
|||||||||
|
Current operating lease liabilities
|
51,897
|
51,644
|
54,057
|
|||||||||
|
Current portion of long-term debt
|
3,000
|
3,000
|
3,000
|
|||||||||
|
Current liabilities held for sale
|
—
|
—
|
50,174
|
|||||||||
|
Total current liabilities
|
409,937
|
345,983
|
412,475
|
|||||||||
|
Noncurrent liabilities:
|
||||||||||||
|
Long-term debt
|
285,621
|
286,115
|
327,600
|
|||||||||
|
Long-term operating lease liabilities
|
189,607
|
176,032
|
192,055
|
|||||||||
|
Deferred income taxes
|
25,410
|
24,975
|
25,375
|
|||||||||
|
Other liabilities
|
85,590
|
82,309
|
89,646
|
|||||||||
|
Noncurrent liabilities held for sale
|
—
|
—
|
82,793
|
|||||||||
|
Total noncurrent liabilities
|
586,228
|
569,431
|
717,469
|
|||||||||
|
Total liabilities
|
996,165
|
915,414
|
1,129,944
|
|||||||||
|
Commitments and contingencies
|
||||||||||||
|
Redeemable noncontrolling interest
|
2,761
|
2,852
|
3,187
|
|||||||||
|
Shareholders' equity:
|
||||||||||||
|
Common stock, $0.01 par value per share, 200,000 shares authorized; 52,089, 51,871, and 54,649 shares outstanding as of September 30, 2020, June 30,
2020, and September 30, 2019, respectively
|
810
|
807
|
805
|
|||||||||
|
Additional paid-in capital
|
508,487
|
504,434
|
492,151
|
|||||||||
|
Retained earnings
|
1,947,498
|
1,927,568
|
2,027,263
|
|||||||||
|
Accumulated other comprehensive loss
|
(8,612
|
)
|
(9,055
|
)
|
(176,739
|
)
|
||||||
|
Treasury stock, at cost, 28,912, 28,794, and 25,862 shares as of September 30, 2020, June 30, 2020, and September 30, 2019, respectively
|
(1,117,212
|
)
|
(1,113,333
|
)
|
(1,016,287
|
)
|
||||||
|
Total shareholders' equity
|
1,330,971
|
1,310,421
|
1,327,193
|
|||||||||
|
Total liabilities and shareholders' equity
|
$
|
2,329,897
|
$
|
2,228,687
|
$
|
2,460,324
|
||||||
|
Three Months Ended
|
||||||||
|
September 30,
|
||||||||
|
2020
|
2019
|
|||||||
|
Revenue
|
$
|
268,241
|
$
|
254,613
|
||||
|
Operating cost and expense:
|
||||||||
|
Cost of educational services
|
113,698
|
128,034
|
||||||
|
Student services and administrative expense
|
100,178
|
99,087
|
||||||
|
Restructuring expense
|
4,223
|
6,530
|
||||||
|
Business acquisition and integration expense
|
13,436
|
—
|
||||||
|
Gain on sale of assets
|
—
|
(4,779
|
)
|
|||||
|
Total operating cost and expense
|
231,535
|
228,872
|
||||||
|
Operating income
|
36,706
|
25,741
|
||||||
|
Other income (expense):
|
||||||||
|
Interest and dividend income
|
1,004
|
678
|
||||||
|
Interest expense
|
(3,692
|
)
|
(5,328
|
)
|
||||
|
Investment gain
|
518
|
23
|
||||||
|
Net other expense
|
(2,170
|
)
|
(4,627
|
)
|
||||
|
Income from continuing operations before income taxes
|
34,536
|
21,114
|
||||||
|
Provision for income taxes
|
(7,090
|
)
|
(3,706
|
)
|
||||
|
Income from continuing operations
|
27,446
|
17,408
|
||||||
|
Discontinued operations:
|
||||||||
|
Loss from discontinued operations before income taxes
|
(10,084
|
)
|
(2,883
|
)
|
||||
|
Benefit from (provision for) income taxes
|
2,477
|
(273
|
)
|
|||||
|
Loss from discontinued operations
|
(7,607
|
)
|
(3,156
|
)
|
||||
|
Net income
|
19,839
|
14,252
|
||||||
|
Net loss attributable to redeemable noncontrolling interest
|
91
|
109
|
||||||
|
Net income attributable to Adtalem Global Education
|
$
|
19,930
|
$
|
14,361
|
||||
|
Amounts attributable to Adtalem Global Education:
|
||||||||
|
Net income from continuing operations
|
$
|
27,537
|
$
|
17,517
|
||||
|
Net loss from discontinued operations
|
(7,607
|
)
|
(3,156
|
)
|
||||
|
Net income attributable to Adtalem Global Education
|
$
|
19,930
|
$
|
14,361
|
||||
|
Earnings (loss) per share attributable to Adtalem Global Education:
|
||||||||
|
Basic:
|
||||||||
|
Continuing operations
|
$
|
0.52
|
$
|
0.32
|
||||
|
Discontinued operations
|
$
|
(0.14
|
)
|
$
|
(0.06
|
)
|
||
|
Net
|
$
|
0.38
|
$
|
0.26
|
||||
|
Diluted:
|
||||||||
|
Continuing operations
|
$
|
0.52
|
$
|
0.31
|
||||
|
Discontinued operations
|
$
|
(0.14
|
)
|
$
|
(0.06
|
)
|
||
|
Net
|
$
|
0.38
|
$
|
0.26
|
||||
|
Weighted-average shares outstanding:
|
||||||||
|
Basic shares
|
52,464
|
55,493
|
||||||
|
Diluted shares
|
52,797
|
56,140
|
||||||
|
Three Months Ended
|
||||||||
|
September 30,
|
||||||||
|
2020
|
2019
|
|||||||
|
Operating activities:
|
||||||||
|
Net income
|
$
|
19,839
|
$
|
14,252
|
||||
|
Loss from discontinued operations
|
7,607
|
3,156
|
||||||
|
Income from continuing operations
|
27,446
|
17,408
|
||||||
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
|
Stock-based compensation expense
|
4,004
|
5,223
|
||||||
|
Amortization and adjustments to operating lease assets
|
14,639
|
12,804
|
||||||
|
Depreciation
|
8,975
|
8,393
|
||||||
|
Amortization of intangible assets
|
2,518
|
2,534
|
||||||
|
Amortization of deferred debt issuance costs
|
392
|
392
|
||||||
|
Provision for bad debts
|
1,723
|
5,554
|
||||||
|
Deferred income taxes
|
4,346
|
2,954
|
||||||
|
Loss on disposals, accelerated depreciation, and adjustments to property and equipment
|
1,486
|
1,053
|
||||||
|
Realized and unrealized gain on investments
|
(518
|
)
|
(22
|
)
|
||||
|
Realized gain on sale of assets
|
—
|
(4,779
|
)
|
|||||
|
Changes in assets and liabilities:
|
||||||||
|
Accounts receivable
|
(13,356
|
)
|
(38,206
|
)
|
||||
|
Prepaid expenses and other current assets
|
(1,735
|
)
|
(13,646
|
)
|
||||
|
Accounts payable
|
2,089
|
(7,566
|
)
|
|||||
|
Accrued payroll and benefits
|
(17,341
|
)
|
(16,593
|
)
|
||||
|
Accrued liabilities
|
(443
|
)
|
(2,417
|
)
|
||||
|
Deferred revenue
|
76,664
|
72,589
|
||||||
|
Operating lease liabilities
|
(12,700
|
)
|
(13,681
|
)
|
||||
|
Other assets and liabilities
|
(13,535
|
)
|
1,482
|
|||||
|
Net cash provided by operating activities-continuing operations
|
84,654
|
33,476
|
||||||
|
Net cash (used in) provided by operating activities-discontinued operations
|
(4,727
|
)
|
13,992
|
|||||
|
Net cash provided by operating activities
|
79,927
|
47,468
|
||||||
|
Investing activities:
|
||||||||
|
Capital expenditures
|
(14,443
|
)
|
(10,436
|
)
|
||||
|
Proceeds from sales of marketable securities
|
1,014
|
290
|
||||||
|
Purchases of marketable securities
|
(963
|
)
|
(292
|
)
|
||||
|
Proceeds from sale of assets
|
—
|
6,421
|
||||||
|
Net cash used in investing activities-continuing operations
|
(14,392
|
)
|
(4,017
|
)
|
||||
|
Net cash used in investing activities-discontinued operations
|
—
|
(1,728
|
)
|
|||||
|
Net cash used in investing activities
|
(14,392
|
)
|
(5,745
|
)
|
||||
|
Financing activities:
|
||||||||
|
Proceeds from exercise of stock options
|
55
|
828
|
||||||
|
Employee taxes paid on withholding shares
|
(3,921
|
)
|
(5,045
|
)
|
||||
|
Proceeds from stock issued under Colleague Stock Purchase Plan
|
31
|
—
|
||||||
|
Repurchases of common stock for treasury
|
—
|
(40,255
|
)
|
|||||
|
Borrowings under credit facility
|
—
|
30,000
|
||||||
|
Repayments under credit facility
|
(750
|
)
|
(100,750
|
)
|
||||
|
Proceeds from down payment on seller loan
|
—
|
5,200
|
||||||
|
Payment for purchase of redeemable noncontrolling interest of subsidiary
|
—
|
(6,247
|
)
|
|||||
|
Net cash used in financing activities-continuing operations
|
(4,585
|
)
|
(116,269
|
)
|
||||
|
Net cash used in financing activities-discontinued operations
|
—
|
(480
|
)
|
|||||
|
Net cash used in financing activities
|
(4,585
|
)
|
(116,749
|
)
|
||||
|
Effect of exchange rate changes on cash, cash equivalents and restricted cash
|
62
|
(6,750
|
)
|
|||||
|
Net increase (decrease) in cash, cash equivalents and restricted cash
|
61,012
|
(81,776
|
)
|
|||||
|
Cash, cash equivalents and restricted cash at beginning of period
|
501,105
|
300,467
|
||||||
|
Cash, cash equivalents and restricted cash at end of period
|
562,117
|
218,691
|
||||||
|
Less: cash, cash equivalents and restricted cash of discontinued operations at end of period
|
—
|
96,902
|
||||||
|
Cash, cash equivalents and restricted cash at end of period
|
$
|
562,117
|
$
|
121,789
|
||||
|
Three Months Ended
|
||||||||||||
|
September 30,
|
||||||||||||
|
2020
|
2019
|
Increase
(Decrease) |
||||||||||
|
Revenue:
|
||||||||||||
|
Medical and Healthcare
|
$
|
218,826
|
$
|
207,487
|
5.5
|
%
|
||||||
|
Financial Services
|
49,415
|
47,126
|
4.9
|
%
|
||||||||
|
Total consolidated revenue
|
$
|
268,241
|
$
|
254,613
|
5.4
|
%
|
||||||
|
Operating income (loss):
|
||||||||||||
|
Medical and Healthcare
|
$
|
53,010
|
$
|
28,500
|
86.0
|
%
|
||||||
|
Financial Services
|
7,272
|
2,128
|
241.7
|
%
|
||||||||
|
Home Office and Other
|
(23,576
|
)
|
(4,887
|
)
|
(382.4
|
)%
|
||||||
|
Total consolidated operating income
|
$
|
36,706
|
$
|
25,741
|
42.6
|
%
|
||||||
|
•
|
Restructuring charges primarily related to real estate consolidations at Adtalem’s home office and ACAMS and the sale of Becker’s courses for
healthcare students.
|
|
•
|
Business acquisition and integration expense include expenses related to the pending Walden University acquisition.
|
|
•
|
Gain on the sale of Adtalem’s Columbus, Ohio, campus facility.
|
|
•
|
Loss from discontinued operations include the operations of Adtalem Brazil, Carrington, and DeVry University.
|
|
Three Months Ended
|
||||||||||||
|
September 30,
|
||||||||||||
|
2020
|
2019
|
Increase
(Decrease) |
||||||||||
|
Medical and Healthcare:
|
||||||||||||
|
Operating income (GAAP)
|
$
|
53,010
|
$
|
28,500
|
86.0
|
%
|
||||||
|
Restructuring expense
|
—
|
127
|
NM
|
|||||||||
|
Operating income excluding special items (non-GAAP)
|
$
|
53,010
|
$
|
28,627
|
85.2
|
%
|
||||||
|
Financial Services:
|
||||||||||||
|
Operating income (GAAP)
|
$
|
7,272
|
$
|
2,128
|
241.7
|
%
|
||||||
|
Restructuring expense
|
1,415
|
1,979
|
(28.5
|
)%
|
||||||||
|
Operating income excluding special items (non-GAAP)
|
$
|
8,687
|
$
|
4,107
|
111.5
|
%
|
||||||
|
Home Office and Other:
|
||||||||||||
|
Operating loss (GAAP)
|
$
|
(23,576
|
)
|
$
|
(4,887
|
)
|
(382.4
|
)%
|
||||
|
Restructuring expense
|
2,808
|
4,424
|
(36.5
|
)%
|
||||||||
|
Business acquisition and integration expense
|
13,436
|
—
|
NM
|
|||||||||
|
Gain on sale of assets
|
—
|
(4,779
|
)
|
NM
|
||||||||
|
Operating loss excluding special items (non-GAAP)
|
$
|
(7,332
|
)
|
$
|
(5,242
|
)
|
(39.9
|
)%
|
||||
|
Adtalem Global Education:
|
||||||||||||
|
Operating income (GAAP)
|
$
|
36,706
|
$
|
25,741
|
42.6
|
%
|
||||||
|
Restructuring expense
|
4,223
|
6,530
|
(35.3
|
)%
|
||||||||
|
Business acquisition and integration expense
|
13,436
|
—
|
NM
|
|||||||||
|
Gain on sale of assets
|
—
|
(4,779
|
)
|
NM
|
||||||||
|
Operating income excluding special items (non-GAAP)
|
$
|
54,365
|
$
|
27,492
|
97.7
|
%
|
||||||
|
Three Months Ended
|
||||||||
|
September 30,
|
||||||||
|
2020
|
2019
|
|||||||
|
Net income attributable to Adtalem (GAAP)
|
$
|
19,930
|
$
|
14,361
|
||||
|
Restructuring expense
|
4,223
|
6,530
|
||||||
|
Business acquisition and integration expense
|
13,436
|
—
|
||||||
|
Gain on sale of assets
|
—
|
(4,779
|
)
|
|||||
|
Income tax impact on non-GAAP adjustments (1)
|
(3,998
|
)
|
(343
|
)
|
||||
|
Loss from discontinued operations
|
7,607
|
3,156
|
||||||
|
Net income from continuing operations attributable to Adtalem excluding special items (non-GAAP)
|
$
|
41,198
|
$
|
18,925
|
||||
|
Three Months Ended
|
||||||||
|
September 30,
|
||||||||
|
2020
|
2019
|
|||||||
|
Earnings per share, diluted (GAAP)
|
$
|
0.38
|
$
|
0.26
|
||||
|
Effect on diluted earnings per share:
|
||||||||
|
Restructuring expense
|
0.08
|
0.12
|
||||||
|
Business acquisition and integration expense
|
0.25
|
-
|
||||||
|
Gain on sale of assets
|
-
|
(0.09
|
)
|
|||||
|
Income tax impact on non-GAAP adjustments (1)
|
(0.08
|
)
|
(0.01
|
)
|
||||
|
Loss from discontinued operations
|
0.14
|
0.06
|
||||||
|
Earnings per share from continuing operations excluding special items, diluted (non-GAAP)
|
$
|
0.78
|
$
|
0.34
|
||||
|
Diluted shares used in EPS calculation
|
52,797
|
56,140
|
||||||
|
Three Months Ended
|
Twelve Months Ended
|
|||||||||||
|
September 30,
|
September 30,
|
|||||||||||
|
2020
|
2019
|
2020
|
||||||||||
|
Net cash provided by operating activities-continuing operations (GAAP)
|
$
|
84,654
|
$
|
33,476
|
$
|
200,743
|
||||||
|
Capital expenditures
|
(14,443
|
)
|
(10,436
|
)
|
(48,144
|
)
|
||||||
|
Free cash flow (non-GAAP)
|
$
|
70,211
|
$
|
23,040
|
$
|
152,599
|
||||||
|
Year Ended
|
||||
|
June 30, 2021
|
||||
|
Expected earnings per share, diluted (GAAP)
|
$
|
2.46 to 2.57 | ||
|
Expected effects on diluted earnings per share:
|
||||
|
Restructuring expense
|
0.08
|
|||
|
Business acquisition and integration expense
|
0.25
|
|||
|
Income tax impact on non-GAAP adjustments(1)
|
(0.08
|
)
|
||
|
Loss from discontinued operations
|
0.14
|
|||
|
Expected earnings per share from continuing operations excluding special items, diluted (non-GAAP)(2)
|
$
|
2.85 to 2.96 | ||
|
Year over year increase
|
25-30
|
%
|
||
|
Diluted shares used in EPS calculation
|
52,797
|
|||
|
Year Ended
|
||||
|
June 30, 2020
|
||||
|
Loss per share, diluted (GAAP)
|
$
|
(1.58
|
)
|
|
|
Effect on diluted earnings per share:
|
||||
|
Restructuring expense
|
0.53
|
|||
|
Gain on sale of assets
|
(0.09
|
)
|
||
|
Gain on derivative
|
(2.05
|
)
|
||
|
Tax Cuts and Jobs Act of 2017
|
(0.04
|
)
|
||
|
Net tax benefit for a former subsidiary investment loss
|
(0.47
|
)
|
||
|
Income tax impact on non-GAAP adjustments(1)
|
(0.10
|
)
|
||
|
Loss from discontinued operations
|
6.09
|
|||
|
Earnings per share from continuing operations excluding special items, diluted (non-GAAP)
|
$
|
2.28
|
||
|
Diluted shares used in EPS calculation
|
54,094
|
|||